Chiranjeevi Pasala

Research Scholar

Chiranjeevi Pasala

Research Scholar

I completed my doctoral degree in Bioinformatics from Sri Venkateswara Institute of Medical Sciences (SVIMS) University, Tirupati, Andhra Pradesh (India). During my Ph.D., I investigated the pathogen-specific potent therapeutic targets vital for multidrug-resistant Helicobacter pylori strains (cause peptic ulcers to lethal gastric cancers) of different geographical regions through comparative genomics and subtractive proteomic approaches. This study paved a way to build receptor-ligand structural models and designed inhibitors for potent therapeutic targets of the pathogen through high-throughput virtual screening and multi-strategic computational methods which offer novel lead moieties to extend further bench to bedside translational experimental research. Subsequent identification of protein vaccine candidates led to design promiscuous immunogenic epitope-driven subunit vaccine cocktails through pan-proteomic reverse vaccinology. I have worked in collaboration to explore novel bioactive chemical space for communicable (M. tuberculosis) and non-communicable diseases (cancers). Also, I worked on transcriptome (RNAseq) of Amrasca biguttula, a pesticide-resistant notorious bug commonly known as the cotton jassid and studied dynamic structural and evolutionary characteristics for the first time to unravel vital inferences in RNAi gene silencing mechanism.

I am currently working as a Postdoctoral research scholar (Computational Chemical Biology) in the laboratory of Prof. Dr. Gabriela Chiosis at Memorial Sloan Kettering Cancer Center. My research aims to unveil hidden internal (atomic-level) cryptic motions and global conformational dynamic plasticity of proteins in response to congeneric novel probes in the biological milieu through dynamics simulations along with determining kinetic profiles, thermodynamic energy landscapes and the degree of drug-dissociation rate (Koff). I study epichaperome targeting drug candidates and compound-specific conformational perturbations and functional dynamics of epichaperome components and interaction partners. Epichaperomes have emerged as a translationally significant gateway to target and control dysfunctional protein-protein interaction networks (i.e., interactomes), and epichaperome agents have translated to clinic in cancer and neurodegenerative diseases as both drugs and companion diagnostics.


Research Papers

  1. Katari SK, Pasala C, Nalamolu RM, Bitla AR, Umamaheswari A. In silico trials to design potent inhibitors against matrilysin (MMP-7). J Biomol Struct Dyn. 2021, 18:1-12. 
  2. 2. Nagalakshmamma V, Venkataswamy M, Pasala C, Uma Maheswari A, Thyaga Raju K, Nagaraju C, Chalapathi PV. A study on MAPK/ERK and CDK2-Cyclin-E signal switch “on and of f” in cell proliferation by bis urea derivatives of 1, 4-Diisocyanatobenzene. Bioorg Chem. 2021, 112:104940.
  3. Vadabingi N, MallepoguV, Pasala C, Amineni U, Kedam T, Chamarthi N, Ponne V.C. Design, Synthesis, anti-tobacco mosaic viral and molecule docking simulations of Urea/Thiourea derivatives of 2-(piperazine-1-yl)-pyrimidine and 1-(4-Fluoro/4-Chloro phenyl)-piperazine and 1-(4-Chloro phenyl)-piperazine-A study, Bioorganic Chemistry. 2020, 104084, ISSN 0045- 2068.
  4. Kodidela S, Shaik FB, Chinta V, Mohammad SA, Pasala C, Mittameedi CM, Maddu N, Wudayagiri R, Nallanchakravarthula V. Possible ameliorative role of green tea on chronic alcohol mediated renal toxicity of STZ -induced diabetic rats, Clinical Nutrition Experimental, 2020, 34:1-25.
  5. Pasala C, Chilamakuri CSR, Katari SK, Nalamolu RM, Bitla AR, Umamaheswari A. An in silico study: Novel targets for potential drug and vaccine design against drug resistant H. pylori. Microb Pathog. 2018, 122:156-161.
  6. Pasala C, Chilamakuri CSR, Katari SK, Nalamolu RM, Bitla AR, Amineni U. Epitope- driven common subunit vaccine design against H. pylori strains. J Biomol Struct Dyn. 2019, 37(14):3740-3750.
  7. Pasala C, Katari, SK, Nalamolu, RM, Bitla AR, Umamaheswari A. Hierarchical- clustering, scaffold-mining exercises, and dynamics simulations for effectual inhibitors against LipidA biosynthesis of Helicobacter pylori. Cel. Mol. Bioeng. 2019, 12 (3):255–274.
  8. Pasala C, Katari SK, Nalamolu RM, Bitla AR, AmineniU. In silico probing exercises, bioactive- CurriculumVitae ChiranjeeviPasala, PhD 5 conformational and dynamic simulations strategies for designing and promoting selective therapeutics against Helicobacter pylori strains. J Mol Graph Model. 2019, 92:167-179.
  9. Pasala C, Katari SK, Nalamolu RM, Aparna RB, Alexander SP, Amineni U. Integration of binding potency estimations and stability assessments for therapeutic design against MurG of H. pylori. J Biomol Struct Dyn. 2019, 37(supplement 1):34-35.
  10. Pasala C, Katari SK, Nalamolu RM, Aparna RB, Amineni U. Integration of core hopping, quantum-mechanics, molecular mechanics coupled binding-energy estimations and dynamic simulations for fragment-based novel therapeutic scaffolds against Helicobacter pylori strains. Comput Biol Chem. 2019, 83:107126.
  11. Chiranjeevi P, Sandeep S, Pradeep N, Hema K, Sudheer Kumar K, Ravina Madhulitha N and Umamaheswari A. Inhibitor Design for VacA Toxin of Helicobacter pylori. Journal of Proteomics & Bioinformatics. 2016, 9(9):220-225.
  12. Satuluri SH, Katari SK, Pasala C, Amineni U. Novel and potent inhibitors for dihydropteroate synthase of Helicobacter pylori. J Recept Signal Transduct Res. 2020, 40(3):246-256.
  13. Sudheer Kumar K., Chiranjeevi P., Ravina Madhulitha N., Umakanth Naik V and Umamaheswari A. Potent MMP-14 antagonist design through screening, docking and dynamics studies. J Biomol Struct Dyn. 2019, 37(supplement 1): 40- 42.
  14. Ravina MadhulithaN., Sudheer Kumar K., Chiranjeevi P., SivaRanjani P and Umamaheswari A. Identification of potential inhibitors for AroG against Mycobacterium tuberculosis. Journal of Biomolecular Structure and Dynamics. 2019, 37(supplement 1): 29-30.
  15. Sivaranjani P., Umakanth Naik V., RavinaMadhulitha N., Sudheer Kumar K., ChiranjeeviP., Sharon priya Alexander and Umamaheswari A. Design of Novel Antimycobacterial Molecule TargetingShikimatePathway of M. tuberculosis. Indian Journal of Pharmaceutical Sciences. 2019, 81(3): 438-447.
  16. Ravina Madhulitha N., ChiranjeeviP.,Sudheer Kumar K and Umamaheswari A. Discovery of common putative drug targets and vaccine candidates for Mycobacterium tuberculosis. Journal of Drug Delivery and Therapeutics. 2019, 9(2-s): 67-71.
  17. Ravina Madhulitha N., Pradeep N., Sandeep S., Hema K., Chiranjeevi P., Sudheer Kumar K and Umamaheswari A. E-Pharmacophore Model Assisted Discovery of Novel Antagonists of nNOS. Biochemistry and Analytical Biochemistry. 2017, 6(1): 1-9.
  18. Ravina Madhulitha N., Sushmitha N., Chiranjeevi P and Umamaheswari A (2016) Identification of novel antagonists for DNA processing chain A (DprA) of H. influenza. International Journal of Computational science, Mathematics and Engineering - SpecialIssue on Computational Science, Mathematics and Biology. IJCSME-SCSMB-16-Mar ch- 2016.
  19. Katari SK, Natarajan P, Swargam S, Kanipakam H, Pasala C, Umamaheswari A. Inhibitor CurriculumVitae ChiranjeeviPasala, PhD 6 design against JNK1 through e-pharmacophore modeling docking and molecular dynamics simulations. J Recept Signal Transduct Res. 2016, 36(6):558-571.
  20. Sivakumari N., ChiranjeeviP.,Pradhan D., Umamaheswari A. Discovery of Potent Inhibitors against GTP Pyrophosphokinase of NeisseriameningitidisSerogroupB. International Journal of Scientific and Engineering Research. 2015, 6(2): 273-278.
  21. Hema K., Vani Priyadarshini I., SandeepS., Pradeep N., ChiranjeeviP. and Umamaheswari A. Subunit vaccine design against pathogens causing atherosclerosis. J Biomol Struct Dyn. 2015, 33 (supplement 1):135-136.